STAT3 and graft versus host disease: In contrast, the recipients given 2.5 to 0.625 × 106 STAT3–/– T cells did not show obvious clinical GVHD, and nearly all recipients given 2.5 or 1.25 × 106 STAT3–/– T cells eliminated ALL tumor cells and survived for more than 100 days.